In Brief: Eclipse Surgical Technologies
This article was originally published in The Gray Sheet
Executive Summary
Eclipse Surgical Technologies: Results of a double-blinded, multicenter Phase II transmyocardial revascularization trial using the firm's Eclipse 2000 laser show that 86% of patients experienced an improvement in anginal symptoms of two class levels or better at three month follow-up, the firm reports. Six-month follow-up data from the trial will be submitted this summer in support of a premarket approval application for the device ("The Gray Sheet" March 31, I&W-8)...